| Field | Specification |
|---|---|
| Alternative names | Vitamin B9 disodium; Vitamin M disodium |
| CAS no. | |
| Applications | |
| Source | Endogenous metabolite |
| Molecular weight | |
| Molecular formula | C19H17N7Na2O6 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Folic acid disodium, also known as Vitamin B9 disodium and Vitamin M disodium, is an orally active disodium salt form of Folic acid with an intrinsic dissolution rate (IDR) of 4.96 × 10⁵ g/s[1]. It serves as a cofactor in single-carbon transfer reactions and has protective effects against neural tube defects, ischemic events, and cancer, whereas its overload impairs brain development during embryogenesis and promotes growth of precancerous altered cells; Folic acid deficiency, in turn, leads to megaloblastic anemia[2]. It is supplied as a light yellow to yellow solid (C19H17N7Na2O6, MW 485.36) at 98.56% purity.
Physical & Chemical Properties
| CAS Number | 29704-76-5 |
|---|---|
| Molecular Formula | C19H17N7Na2O6 |
| Molecular Weight | 485.36 g/mol |
| Purity | 98.56% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| Structure Classification | Others |
| SMILES | O=C(O[Na])CC[C@@H](C(O[Na])=O)NC(C1=CC=C(NCC2=CN=C3N=C(N)NC(C3=N2)=O)C=C1)=O |
| Signaling Pathway | Metabolic Enzyme/Protease; Cell Cycle/DNA Damage |
| Initial Source | Endogenous metabolite |
| Solubility | In Vitro: H2O: ≥ 100 mg/mL (206.03 mM) * "≥" means soluble, but saturation unknown. |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description. Peer-reviewed publications that used this product are listed under References.
[1]. Braga D., et al., Folic Acid in the Solid State: A Synergistic Computational, Spectroscopic, and Structural Approach, Crystal Growth & Design, 2016, 16, 4, 2218–222.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| H2O | ≥ 100 mg/mL (206.03 mM) | — |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
Data provided by the manufacturer.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Bidirectional modulation of glycolysis using a multifunctional nanocomposite hydrogel promotes bone fracture healing in type 2 diabetes mellitus. Bioact Mater 2025 Apr 8:50:152-170. PMID: 40256330
The nuclear receptor ESRRA is a crucial regulator of acute kidney injury through inhibition of the lipophagy-ferroptosis axis. Autophagy 2026 Apr 27. PMID: 42041131
Nuclear localization of MTHFD2 is required for correct mitosis progression. Nat Commun 2024 Nov 12;15(1):9529. PMID: 39532843
c-Myc-PANK3-EMT axis regulates the structure and function of intestinal barrier in ulcerative colitis. J Adv Res 2025 Dec 8:S2090-1232(25)00996-8. PMID: 41371401
Leocarpinolide B alleviates epithelial tubular mitochondrial dysfunction via macrophage exosomal miR-204-5p/TFAM axis in AKI-CKD transition. J Nanobiotechnology 2026 Apr 10;24(1):477. PMID: 41963952
Folate-modified biomimetic nanovesicles loaded with a PU.1 inhibitor alleviate atherosclerosis by suppressing inflammation. J Nanobiotechnology 2025 Dec 5. PMID: 41345629
Gene Therapy for Inflammatory Cascade in Intrauterine Injury with Engineered Extracellular Vesicles Hybrid Snail Mucus-enhanced Adhesive Hydrogels. Adv Sci (Weinh) 2025 Jan;12(1):e2410769. PMID: 39454114
Gestational palmitic acid suppresses embryonic GATA-binding protein 4 signaling and causes congenital heart disease. Cell Rep Med 2023 Mar 21;4(3):100953. PMID: 36809766
The E3 ubiquitin ligase Itch plays an essential role in kidney fibrosis by inhibiting Dvl2/GSK3β/β-catenin signaling pathway. Cell Death Differ 2026 May 22. PMID: 42168361
Creating Chemiluminescence Signature Arrays Coupled with Machine Learning for Alzheimer's Disease Serum Diagnosis. Research (Wash D C) 2025 May 12:8:0653. PMID: 40357359
